Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES)

Online journal article in Laboratory Management that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Write a Review

List Price: $20.00
Member Price: $15.00

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Join

Item Details:

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Discuss application of Programmed death ligand 1 (PD-L1) immunohistochemistry and tumor mutational burden (TMB) testing in immune-oncology,...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Discuss application of Programmed death ligand 1 (PD-L1) immunohistochemistry and tumor mutational burden (TMB) testing in immune-oncology, including potential strengths and weaknesses of each.
List technical factors that can influence detection of tumor mutational burden (TMB) as a biomarker for immune-oncology.
Outline potential ways that whole exome sequencing (WES) TMB testing can be improved and strengthened for enhanced precision, reproducibility, and comparability across multiple laboratories.

View More View Less

First Name *
Last Name *
Email *
Customer ID

Name *
Country Code *
Phone Number *
Scheduled Date *
Scheduled Time *
Customer Id

Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES)

Item Details:

Bought This Bought That ...